Moberg Pharma Future Growth
Future criteria checks 2/6
Moberg Pharma is forecast to grow earnings and revenue by 66.5% and 105% per annum respectively while EPS is expected to grow by 41.2% per annum.
Key information
66.5%
Earnings growth rate
41.2%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 105.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 88 | 2 | 18 | 31 | 1 |
| 12/31/2025 | 22 | -14 | -40 | -15 | 1 |
| 12/31/2024 | 10 | -17 | -96 | -25 | 1 |
| 9/30/2024 | 9 | -18 | -115 | -27 | N/A |
| 6/30/2024 | 5 | -23 | -134 | -33 | N/A |
| 3/31/2024 | 1 | -23 | -139 | -31 | N/A |
| 12/31/2023 | N/A | -21 | -157 | -33 | N/A |
| 9/30/2023 | N/A | -18 | -134 | -29 | N/A |
| 6/30/2023 | 0 | -16 | -105 | -21 | N/A |
| 3/31/2023 | 0 | -16 | -96 | -16 | N/A |
| 12/31/2022 | 0 | -16 | -85 | -17 | N/A |
| 9/30/2022 | 0 | -17 | -75 | -14 | N/A |
| 6/30/2022 | N/A | -16 | -70 | -12 | N/A |
| 3/31/2022 | N/A | -16 | -56 | -7 | N/A |
| 12/31/2021 | N/A | -16 | -47 | -15 | N/A |
| 9/30/2021 | 34 | 8 | -44 | -9 | N/A |
| 6/30/2021 | 34 | 7 | -46 | -12 | N/A |
| 3/31/2021 | 34 | 5 | -58 | -16 | N/A |
| 12/31/2020 | 34 | 7 | -52 | -10 | N/A |
| 6/30/2020 | 50 | 20 | -47 | 4 | N/A |
| 6/30/2019 | 31 | -8 | -140 | -76 | N/A |
| 3/31/2019 | 455 | 31 | 15 | 88 | N/A |
| 12/31/2018 | 5 | -28 | -10 | 74 | N/A |
| 9/30/2018 | 341 | 9 | -2 | 87 | N/A |
| 6/30/2018 | 340 | 19 | N/A | 109 | N/A |
| 3/31/2018 | 334 | 6 | N/A | 68 | N/A |
| 12/31/2017 | 439 | 11 | N/A | 54 | N/A |
| 9/30/2017 | 438 | -1 | N/A | 30 | N/A |
| 6/30/2017 | 434 | 0 | N/A | -44 | N/A |
| 3/31/2017 | 369 | 35 | N/A | -17 | N/A |
| 12/31/2016 | 334 | 33 | N/A | -18 | N/A |
| 9/30/2016 | 299 | 36 | N/A | -21 | N/A |
| 6/30/2016 | 261 | 32 | N/A | 12 | N/A |
| 3/31/2016 | 282 | 9 | N/A | 32 | N/A |
| 12/31/2015 | 286 | 26 | N/A | 31 | N/A |
| 9/30/2015 | 276 | 25 | N/A | 34 | N/A |
| 6/30/2015 | 260 | 20 | N/A | 30 | N/A |
| 3/31/2015 | 226 | 19 | N/A | 14 | N/A |
| 12/31/2014 | 200 | 12 | N/A | 16 | N/A |
| 9/30/2014 | 193 | 12 | N/A | 11 | N/A |
| 6/30/2014 | 179 | 4 | N/A | 1 | N/A |
| 3/31/2014 | 167 | -5 | N/A | -6 | N/A |
| 12/31/2013 | 157 | -11 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MBGP.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MBGP.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MBGP.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MBGP.F's revenue (105% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: MBGP.F's revenue (105% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MBGP.F's Return on Equity is forecast to be high in 3 years time